GSK Shifts Strategy, Axes Adult Vaccine Candidate in $2.1B Affinivax Deal Amid Rising Competition
In a strategic shift, GSK has halted the development of its 24-valent pneumococcal vaccine for adults—a major project from its ...
In a strategic shift, GSK has halted the development of its 24-valent pneumococcal vaccine for adults—a major project from its ...
© 2020 The Lagos Today - Nkali.